

**SOCIAL SECURITY FINANCING BILL 2025:
pharmaceutical companies act responsibly.**

**Emergency agreement reached with the Government
following the 1.2 billion alert on medicines spending.**

Faced with the risk detected by the Social Security Department at the end of last week, the pharmaceutical companies mobilised urgently to ensure that budgetary accuracy and the predictability of healthcare expenditure were preserved.

Despite conflicting analyses of the level of risk involved, the principle of an agreement has been formalised in order to anticipate the consequences that an overspend of €1.2 billion would have on the accounts of companies and the French health insurance system.

The terms of the agreement as part of the Social Security Financing Bill 2025 are as follows:

- The government's commitment to limit the safeguard clause to €1.6 billion has been confirmed.
- To achieve this, the pharmaceutical companies and the government have committed to enter into a contractual agreement to generate savings of €600 million through proper use and delisting (access to a wider panel of medicines with or without prescription).
- Both sides will work together to set up joint management tools, to promote European and French production and to simplify access to innovation.

Moreover, the reform of the calculation of the safeguard clause has been postponed to ensure predictability and sustainability for businesses, in consultation with the sector. This postponement will make it possible to begin the work needed to overhaul the mechanisms for financing and regulating medicines expenditure.

'This agreement should set in motion a reciprocal process of transparency and efficiency, the urgency of which everyone agrees. We will be vigilant. This is the key to preserving our social protection system, while enabling pharmaceutical companies to have the resources they need to fulfil their mission to serve patients' declared Thierry Hulot, President of Leem.